Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

By J. Miguel, K. Weisel, P. Moreau, M. Lacy, K. Song, M. Delforge, L. Karlin, H. Goldschmidt, A. Banos, A. Oriol and 15 more. The Lancet Oncology, 2013

765 citations recorded by the source corpus.

Subfields: Hematology, Oncology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/c2d9ab11b5739b401b8d3d2d135f5d895e4a8519